Two ongoing phase II PTSD studies (NCT05207436, NCT04523922) investigating intranasal oxytocin as an adjunct to prolonged exposure therapy or brief cognitive behavioral therapy will hopefully help clarify matters. The gene discussed is OXT; the disease is post-traumatic stress disorder.